Updated:
DNA Capital
DNA Capital traces to the Bueno family founders of Amil, a Brazilian health insurance and services group later acquired by UnitedHealth Group.
DNA Capital
DNA Capital traces to the Bueno family founders of Amil, a Brazilian health insurance and services group later acquired by UnitedHealth Group. Edson Bueno established the firm before his death; Pedro Bueno and Dulce Bueno continue as principals. The office is headquartered in Hong Kong. Investment activity centers on venture capital and management buyouts. Confirmed holdings include Consensys, Mysten Labs, and Neo4j. The portfolio also encompasses Rede Ímpar Hospital Network and DASA diagnostic operations in Brazil, plus UnitedHealth Group shares. Geographic reach spans Asia, Latin America, and the United States. No public headcount or AUM figures exist. The firm belongs to ABVCAP and LAVCA. Adjacent structures include the Bueno Family Foundation and Movimento Bem Maior. No operational events from the last 24 months appear in available records. DNA Capital operates as a single-family office with direct exposure to operating healthcare businesses in Brazil. This structure creates a distinct link between legacy asset ownership and new venture allocations.
General information
Firm type
Single Family Office
Year founded
2009
AUM
Undisclosed
Location
Region
Asia
Country
Hong Kong
City
San Francisco
Corporate office
Hong Kong
Principals
Pedro Bueno
Partner
Dulce Bueno
Co-founder
Edson Bueno
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at DNA Capital?
Pedro Bueno serves as partner. Dulce Bueno acts as co-founder with prior involvement in Amil.
Where does the underlying wealth come from?
The Bueno family built Amil, a Brazilian healthcare provider sold to UnitedHealth Group.
Does DNA Capital participate in fund commitments or only direct deals?
The firm holds direct positions in Consensys, Mysten Labs, and Neo4j alongside operating assets in Brazil.
What investment stages does DNA Capital typically target?
Activity includes venture capital and management buyouts.
How is DNA Capital related to DASA?
Pedro Bueno serves as CEO of DASA while acting as partner at DNA Capital.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: